Mohamed Abdelaziz/LinkedIn
Jun 9, 2025, 16:49
Mohamed Abdelaziz: Honored to Present My Abstract Poster at ICARO4 by IAEA
Mohamed Abdelaziz, National Oncology Committee member at the Ministry of Health and Population of Egypt, shared a post on LinkedIn:
“Is there a difference between lung SBRT with 6 MV FFF in single vs multiple lung lesions in efficacy, toxicity, and dosimetry in unilateral and bilateral lung lesions? That was our research questions, and I am honored to briefly answer it during my abstract poster presentation at ICARO4 Conference by the International Atomic Energy Agency (IAEA).
We reviewed patient records and planned for a total of 40 patients, and our median follow-up period was 12 months. Regarding efficacy, the local control rate was 92% for single lesions and 85% for multiple lesions. As in dosimetry, there was a significant difference in lung V5 and V20 in single vs multiple lesions, favoring single lesions with lesser volume received 5 Gy and 20 Gy.
As per toxicity-wise, there was no difference, and only G2 pneumonitis was observed in 10% of our patients. So we can conclude that SBRT is a safe and effective treatment and highlights the technique’s potential benefits, especially for patients with complex lesion profiles.”
More posts featuring Mohamed Abdelaziz.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 9, 2025, 16:49
Jun 9, 2025, 16:39
Jun 9, 2025, 16:25
Jun 9, 2025, 16:15
Jun 9, 2025, 15:51
Jun 9, 2025, 15:34
Jun 9, 2025, 15:08
Jun 9, 2025, 14:50